• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
South African Variant Can ‘Break Through’ Pfizer Vaccine, Israeli Study Says

South African Variant Can ‘Break Through’ Pfizer Vaccine, Israeli Study Says

April 11, 2021
Citi Stops Debanking Gun Retailers

Citi Stops Debanking Gun Retailers

June 3, 2025
‘Silly Season’: GOP Senator Now Trailing Opponent In Poll By Over 20 Points, Though Race Far From Over

‘Silly Season’: GOP Senator Now Trailing Opponent In Poll By Over 20 Points, Though Race Far From Over

June 3, 2025
Biden FBI’s Targeting Of ‘Traditional’ Catholics Was Bigger Than Previously Thought, Docs Show

Biden FBI’s Targeting Of ‘Traditional’ Catholics Was Bigger Than Previously Thought, Docs Show

June 3, 2025
GOP Lawmaker to Introduce Resolution to Declare June ‘Family Month’ Instead of ‘Pride Month’

GOP Lawmaker to Introduce Resolution to Declare June ‘Family Month’ Instead of ‘Pride Month’

June 3, 2025
‘Let Me Finish!’: Cory Booker Blows His Lid During Fiery Exchange With Ted Cruz

‘Let Me Finish!’: Cory Booker Blows His Lid During Fiery Exchange With Ted Cruz

June 3, 2025
Peter Doocy Asks Karoline Leavitt ‘How Mad’ Trump Is At Musk After He Attacked ‘Beautiful Bill’

Peter Doocy Asks Karoline Leavitt ‘How Mad’ Trump Is At Musk After He Attacked ‘Beautiful Bill’

June 3, 2025
‘My Voice Was Not Always Heard’ — Ex-DNC Chair Bemoans Being ‘Rubber Stamp’ For Party

‘My Voice Was Not Always Heard’ — Ex-DNC Chair Bemoans Being ‘Rubber Stamp’ For Party

June 3, 2025
America’s Biggest Adversary Looks To Scoop Up Scientists Sent Packing Under Trump

America’s Biggest Adversary Looks To Scoop Up Scientists Sent Packing Under Trump

June 3, 2025
Karoline Leavitt Calls Out WaPo By Name Over Headline About ‘Mysterious’ Decrease In Fentanyl At Border

Karoline Leavitt Calls Out WaPo By Name Over Headline About ‘Mysterious’ Decrease In Fentanyl At Border

June 3, 2025
Newsom Admin Reportedly Holds Closed-Door Business Meetings With Chinese Gov’t Officials

Newsom Admin Reportedly Holds Closed-Door Business Meetings With Chinese Gov’t Officials

June 3, 2025
WaPo Apologizes For Publishing Hamas Propaganda At Face Value

WaPo Apologizes For Publishing Hamas Propaganda At Face Value

June 3, 2025
DAVID BOSSIE: Time For Congress To Pull Back The Curtain On Biden

DAVID BOSSIE: Time For Congress To Pull Back The Curtain On Biden

June 3, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Tuesday, June 3, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home News

South African Variant Can ‘Break Through’ Pfizer Vaccine, Israeli Study Says

by Reuters
April 11, 2021 at 7:47 am
in News
245 7
1
South African Variant Can ‘Break Through’ Pfizer Vaccine, Israeli Study Says

FILE PHOTO: A woman receives a vaccination against the coronavirus disease (COVID-19) at a temporary Clalit healthcare maintenance organisation (HMO) centre, in Herzliya, Israel February 3, 2021. REUTERS/Amir Cohen/File Photo

491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

The coronavirus variant discovered in South Africa can “break through” Pfizer/BioNTech’s COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is low and the research has not been peer reviewed.

The study, released on Saturday, compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease. It matched age and gender, among other characteristics.

The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across all the people studied, according to the study by Tel Aviv University and Israel’s largest healthcare provider, Clalit.

But among patients who had received two doses of the vaccine, the variant’s prevalence rate was eight times higher than those unvaccinated – 5.4% versus 0.7%.

This suggests the vaccine is less effective against the South African variant, compared with the original coronavirus and a variant first identified in Britain that has come to comprise nearly all COVID-19 cases in Israel, the researchers said.

“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection,” said Tel Aviv University’s Adi Stern.

The researchers cautioned, though, that the study only had a small sample size of people infected with the South African variant because of its rarity in Israel.

They also said the research was not intended to deduce overall vaccine effectiveness against any variant, since it only looked at people who had already tested positive for COVID-19, not at overall infection rates.

Pfizer and BioNTech could not be immediately reached for comment outside business hours.

The companies said on April 1 that their vaccine was around 91% effective at preventing COVID-19, citing updated trial data that included participants inoculated for up to six months.

In respect to the South African variant, they said that among a group of 800 study volunteers in South Africa, where B.1.351 is widespread, there were nine cases of COVID-19, all of which occurred among participants who got the placebo. Of those nine cases, six were among individuals infected with the South African variant.

Some previous studies have indicated that the Pfizer/BioNTech shot was less potent against the B.1.351 variant than against other variants of the coronavirus, but still offered a robust defence.

While the results of the study may cause concern, the low prevalence of the South African strain was encouraging, according to Stern.

“Even if the South African variant does break through the vaccine’s protection, it has not spread widely through the population,” said Stern, adding that the British variant may be “blocking” the spread of the South African strain.

Almost 53% of Israel’s 9.3 million population has received both Pfizer doses. Israel has largely reopened its economy in recent weeks while the pandemic appears to be receding, with infection rates, severe illness and hospitalizations dropping sharply. About a third of Israelis are below the age of 16, which means they are still not eligible for the shot.

(Reporting by Maayan Lubell; Editing by Pravin Char)

Tags: Coronavirus Outbreak
Share196Tweet123
Reuters

Reuters

Reuters is an international news organization.

Advertisements

Top Stories June 10th
Top Stories June 7th
Top Stories June 6th
Top Stories June 3rd
Top Stories May 30th
Top Stories May 29th
Top Stories May 24th
Top Stories May 23rd
Top Stories May 21st
Top Stories May 17th

Join Over 6M Subscribers

We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





IJR

    Copyright © 2024 IJR

Trusted Voices On All Sides

  • About Us
  • GDPR Privacy Policy
  • Terms of Service
  • Editorial Standards & Corrections Policy
  • Subscribe to IJR

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls

    Copyright © 2024 IJR

Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th